Home /  All blogs

Abstract presented at EBCC

Breast cancer abstractBreast cancer diagnosis and subtyping by analysing exhaled breath: A pilot study using a portable electronic nose (Aeonose®)  Timmer-Bonte1, S. Grosfeld1, N. Seelen-Janssen1, L. Veenendaal2, F. Zijlstra3.


1Alexander Monro Breast Cancer Hospital, Medical Oncology, Bilthoven, Netherlands; 2Alexander Monro Breast Cancer Hospital, Surgery, Bilthoven, Netherlands; 3Alexander Monro Breast Cancer Hospital, Radiology, Bilthoven, Netherlands


Background: Analysing exhaled breath is a rapidly emerging field of medical diagnostics. Growing evidence suggests pathological conditions can cause metabolic changes in the body resulting in deviations in volatile organic compounds (VOC’s) in exhaled breath. The hand-held electronic nose used in this pilot study is convenient to use and has already proven to be capable of distinguishing patients (pts) suffering from lung cancer and head and neck cancer from healthy controls. Advantages include non-invasiveness and fast results. The objective of the current study is to investigate if exhaled-breath patterns from breast cancer (BC) pts can be distinguished from pts with benign breast pathology or healthy controls.


Methods: Female pts referred to our breast cancer hospital for screening or on suspicion of BC, were subjected to standard diagnostic procedures as per protocol (with a minimum of clinical examination, mammography and in case of BIRADS >2 biopsy). All pts were asked written informed consent for performing an additional breath test. Pts had to breathe into the Aeonose® device (made available for this pilot study by The eNose Company, Zutphen, The Netherlands) for a period of 5 minutes. Collected measurement data were compressed using a Tucker3 algorithm followed by neural network analysis. In this way, the electronic nose has been trained to distinguish between healthy and affected pts.


Results: 185 pts were eligible; the majority was referred because of a palpable lesion or abnormal findings on mammography in the Dutch national screening program. In 56 pts BC was confirmed (biopsy or surgery). In the remaining 129 pts no or benign (e.g. cysts or fibroadenoma) breast disease (no BC) was diagnosed. Based on the measurement data of the VOC’s in exhaled breath, a ROC (Receiver Operating Characteristic)- curve has been created showing only a fair sensitivity and specificity of 68% and 64%, respectively. However, BC is a heterogeneous disease. Therefore, explorative analyses were performed. Indeed, no BC (n = 119) compared to either Invasive Ductal Carcinoma (IDC) (n = 38) or to Invasive Lobular Carcinoma (ILC) (n = 11) showed an improved sensitivity and specificity (IDC 71% and 55%; ILC 100% and 81% respectively). All analyses were cross-validated using a leave-one-out method.


Conclusion: The high sensitivity and specificity values found for (the relatively homogeneous) ILC indicates this technology has potential for convenient, quick, and non-invasive screening of (a)symptomatic patients. Based on our experience we expect the ROC-curve to improve for IDC when increasing numbers in several pathological subtypes can be included. Based on these results we intend to perform a larger multi-centre trial as the Aeonose electronic nose could be a convenient and cost-effective screening test for both patient and staff.


Diagnosing gastrointestinal illnesses using fecal headspace volatile organic compounds

2016-02-15_14-01-48

fecal VOC analysis with Aetholab

“In our own experience, we used the Aetholab, a commercial electronic nose device (The eNose Company, Zutphen, Netherlands) in a preliminary study of 20 C. difficile PCR-positive stool and 53 C. difficile PCR-negative stool. In a similar approach using an artificial neural network for pattern recognition, we were able to classify the stool with 80% sensitivity, 85% specificity, and 84% accuracy.”


46th World Conference on Lung Health

At the 46th World Conference on Lung Health, Cape Town, South Africa (December 2-6, 2015), results from two Aeonose studies on TB were presented:


EP-138-04: Diagnosis of pulmonary and extra-pulmonary tuberculosis in Paraguay using the electronic nose (Paranose study) by R. Coronel et al,

86 participants were evaluated in 2015, 41 patients suffered from pulmonary TB and 45 were healthy controls. Preliminary analyses show sensitivity of 93% and specificity of 89 %.
A paper is in preparation.


EP-212-0: A new tuberculosis-screening tool: a hand-held electronic nose. A cross-sectional field study in Indonesia by A.M. Saktiawati et al.

87 participants from 5 groups (20 TB patients, 20 TB suspects who were later diagnosed as non TB, 20 non-TB patients, 20 healthy matched controls, and 7 MDR-TB patients) have been investigated showing a sensitivity of 92% and a specificity of 88%. More participants are being included.



Afbeelding1


TB study in Venezuela has started!

Recently, a study has started for evaluating the Aeonose for diagnosing tuberculosis in the Warao Amerindian population in Venezuela. This population has a high adult and pediatric TB prevalence (comparable to epidemic regions in Africa). At the same time, HIV prevalence is high as well among adults in some villages (up to 20%).

The study is being coordinated by Dr. Jacobus de Waard, Head of the Tuberculosis Laboratory, Universidad Central de Venezuela.

In December 2014, the study was mentioned in a local newspaper in Caracas, Venezuela.

enose-G

After developing a calibration model for TB in Venezuela, the Aeonose will be evaluated during a blind study.


TB study in Paraguay has started!

A TB study focusing on extra-pulmonary tuberculosis has just started at Instituto de Enfermedades Respiratorias y del Ambiente (INERAM) in Asuncion, Paraguay.

The study is being coordinated by Dr Cecile Magis and Dr Jan-Bart Yntema from Radboud University, Nijmegen, The Netherlands.

First, they will include pulmonary-TB patients and healthy controls in order to build a TB-model for Paraguay. It is important to know if this TB-model differs from models being recorded elsewhere in the world. Next, they will include extra-pulmonary TB patients as mentioned before.

For some impressions, see the pictures below:

Far left: Jan-Bart Yntema. Not in picture: Cecile Magis

Far left: Jan-Bart Yntema. Not in picture: Cecile Magis








Exhaled-breath-test using the Aeonose

Exhaled-breath-test using the Aeonose


Page 5 of 8<<<...34567...>>>